Ahmed Kotb/daiichisankyo.us
Jul 18, 2026, 20:15
Ahmed Kotb: Exploring Qualitative Platelet Defects
Ahmed Kotb, Head of Global Oncology Medical Affairs at Daiichi Sankyo, shared a post on X:
“Qualitative Platelet Defects
Inherited
- Glanzmann: low GPIIb/IIIa – No aggregation except ristocetin
- Bernard–Soulier: low GPIb – Abnormal ristocetin
- Storage pool disease: Absent 2ry wave
Acquired
- Drugs:Aspirin, Clopidogrel, GP IIb/IIIa inhibitor
- Diseases: Uremia, liver disease”
Stay updated with Hemostasis Today.
-
Aug 11, 2026, 16:44The Evolving Treatment Landscape of Hemophilia: From Factor Replacement to Gene Therapy
-
Aug 11, 2026, 16:34Advancing Hemophilia Care Through Training and Local Capacity Building – WFH
-
Aug 11, 2026, 16:26Sabrina H.: The Spectrum of PF4-Mediated Thrombotic Disorders
-
Aug 11, 2026, 16:17Mandy Lauw: From CRTH Training to Clinical Trials
-
Aug 11, 2026, 16:05Obi Light Ogbonnia: From 52 Years of Living With Sickle Cell to a Global Stage
-
Aug 11, 2026, 15:42Iva Pruner: Hemostasis, Thrombosis, and a Little Death Metal
-
Aug 11, 2026, 15:25Bradley Maron։ The AI Revolution in Cardiovascular Drug Development
-
Aug 11, 2026, 15:10Jared Rice: When a Negative DAT Doesn’t Mean the Alloimmune Risk Is Gone
-
Aug 11, 2026, 14:58Manuel De Jesus: Validating the Future of Point-of-Care Anemia Monitoring